Evidence map›Paper›PMID 12522045›Full record

ArticleClinical and diagnostic laboratory immunology2003

Specificity and diversity of antibodies to Mycobacterium tuberculosis arabinomannan.

Josephine Anne D Navoa, Suman Laal, Liise-Anne Pirofski, Gary R McLean, Zhongdong Dai, John B Robbins, Rachel Schneerson, Arturo Casadevall, Aharona Glatman-Freedman

Open access · diamondAbstract read
In one paragraph

Article in Clinical and diagnostic laboratory immunology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Josephine Anne D NavoaDepartment of Pediatrics, Albert Einstein College of Medicine, Bronx, New York, New York 10461, USA.
Suman Laal
Liise-Anne Pirofski
Gary R McLean
Zhongdong Dai
John B Robbins
Rachel Schneerson
Arturo Casadevall
Aharona Glatman-Freedman
Eunice Kennedy Shriver National Institute of Child Health and Human Development · USBipar · FRNew York University · US

Funding

Synergy of Host Defense Mechanisms in the LungR01HL059842 · NHLBI · YESHIVA UNIVERSITY · PI CASADEVALL, ARTURO · 1997 to 2023
$7.4M
PROTECTIVE ANTIBODIES FOR CRYPTOCOCCAL INFECTIONSR01AI033774 · NIAID · YESHIVA UNIVERSITY · PI CASADEVALL, ARTURO · 1994 to 2014
$5.6M
VARIABLE GENE USE AND PNEUMOCOCCAL IMMUNITY IN AIDSR01AI045459 · NIAID · YESHIVA UNIVERSITY · PI PIROFSKI, LIISE-ANNE · 2000 to 2010
$3.9M
Molecular Characterization of C. neoformans AntibodiesR37AI033142 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CASADEVALL, ARTURO · 2007 to 2016
$3.9M
Human Antibodies to Crytococcus NeoformansR01AI035370 · NIAID · YESHIVA UNIVERSITY · PI PIROFSKI, LIISE-ANNE · 1994 to 2009
$3.3M
VARIABLE GENE DEFECTS AND PNEUMOCOCCAL SUSCEPTIBILITYR01AI044374 · NIAID · YESHIVA UNIVERSITY · PI PIROFSKI, LIISE-ANNE · 2001 to 2010
$2.7M
MOLECULAR CHARACTERIZATION OF C NEOFORMANS ANTIBODIESR01AI033142 · NIAID · YESHIVA UNIVERSITY · PI CASADEVALL, ARTURO · 1994 to 2006
$1.7M
STRUCTURE/FUNCTION RELATIONSHIP FOR ANTIBODIES TO M. TUBK08AI001691 · NIAID · YESHIVA UNIVERSITY · PI GLATMAN-FREEDMAN, AHARONA · 1999 to 2003
$495k
Response To Polysaccharide/Oligosaccharide/Peptide-ProteZ01HD001301 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI SCHNEERSON, RACHEL · 1985 to 2008
$362k
Novel Approach for Vaccine Development against M.TbR03AI053192 · NIAID · YESHIVA UNIVERSITY · PI GLATMAN-FREEDMAN, AHARONA · 2002 to 2003
$167k
NHLBI NIH HHS HL059842NHLBI NIH HHS R01 HL059842NIAID NIH HHS AI001691NIAID NIH HHS AI033142NIAID NIH HHS AI033774NIAID NIH HHS AI035370NIAID NIH HHS AI044374NIAID NIH HHS AI045459NIAID NIH HHS AI053192NIAID NIH HHS K08 AI001691NIAID NIH HHS R01 AI033142NIAID NIH HHS R01 AI033774NIAID NIH HHS R01 AI035370NIAID NIH HHS R01 AI044374NIAID NIH HHS R01 AI045459NIAID NIH HHS R03 AI053192NIAID NIH HHS R37 AI033142
6 · The paper itself

Abstract

Arabinomannan (AM) is a polysaccharide antigen of the mycobacterial capsule. However, it is uncertain whether AM constitutes an immunologically distinct fraction of Mycobacterium tuberculosis. In this study, we analyzed the repertoire and specificity of antibodies to AM by using AM-binding murine monoclonal antibodies (MAbs) and human serum samples. Murine MAbs were found to be diverse in their specificity to AM and cross-reactivity with other arabinose-containing mycobacterial polysaccharides, with MAb 9d8 binding exclusively to AM. Human antibodies to AM were detected in serum samples from patients with pulmonary tuberculosis (TB), as well as in those from healthy, purified protein derivative-negative controls, with significantly higher titers among patients. The binding of human antibodies to AM was inhibited by MAb 9d8 in three patients with TB but not in controls. MAb 5c11, which recognizes other mycobacterial arabinose-containing carbohydrates in addition to AM, inhibited the binding of serum samples from 75% of patients and 76% of controls. Analysis of human antibodies with murine MAbs to human V(H) determinants demonstrated diversity among antibodies to AM with qualitative and quantitative differences compared with antibodies to lipoarabinomannan. In summary, our study suggests that antibodies to AM are diverse and heterogeneous with respect to antigen recognition and V(H) determinant expression, with human serum samples containing different subsets of antibodies to AM with the specificities of AM-binding murine MAbs. One MAb and a subset of human antibodies bind AM specifically, suggesting that this polysaccharide is antigenically distinct and is expressed in human infection.

Indexed as

AdolescentAdultAgedAntibodies, BacterialAntibody DiversityAntibody SpecificityCase-Control StudiesConsensus SequenceCross ReactionsFemaleHumansImmunoglobulin Variable RegionMaleMannansMiddle AgedMolecular Sequence DataAntibodies, BacterialarabinomannanImmunoglobulin Variable RegionMannansPolysaccharides, Bacterial

Identifiers

PMID12522045
PMCPMC145285
OpenAlexW2149049493

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.